James Klinger, MD
Pulmonary Disease · Riverside, RINPI 1639123854
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Pfizer accounts for 77.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $2,039 and has fallen 88.6% since, to $233 in 2025.
Across 18 payments — averaging $146.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- United Therapeutics Corporation$316
- Boehringer Ingelheim$135
- Actelion Pharmaceuticals US, Inc.$131
- AstraZeneca$12
Across 32 payments — averaging $85,229 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.6M
- United Therapeutics Corporation$121K
- Pfizer$26K
- Actelion Pharmaceuticals US, Inc.$9K
- Janssen Research & Development, LLC$5K
What the payments were for
- Travel & lodging$1,42954%
- Food & beverage$1,07041%
- Education$1345%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $2,039 |
| United Therapeutics Corporation | 7 | $316 |
| Boehringer Ingelheim | 1 | $135 |
| Actelion Pharmaceuticals US, Inc. | 3 | $131 |
| AstraZeneca | 1 | $12 |
How this compares
$2,633 in reported general payments places this provider in the 75th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 17 | $219,389 |
| OpsumitMacitentan | 13 | $166,974 |
| TracleerBosentan | 11 | $140,743 |
| Ambrisentan | 38 | $78,493 |
| Tadalafil | 40 | $44,055 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $33,268 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $29,764 |
| EliquisApixaban | 32 | $23,139 |
| Sildenafil Citrate | 62 | $17,366 |
| Spiriva RespimatTiotropium Bromide | 14 | $10,142 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,364 |
| XareltoRivaroxaban | 12 | $6,457 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,362 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,003 |
| Bumetanide | 18 | $1,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Tracleer | $131 | $307,71724 claims |
| PfizerEliquis | $2,039 | $23,13932 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $135 | $17,50529 claims |
| AstraZenecaSymbicort | $12 | $3,36211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Riverside
- Corey VentetuoloRiverside$51K
- John LadettoRiverside$39K
- Douglas MartinRiverside$4K
- Matthew BallenbergerRiverside$1K
- Peter KarczmarRiverside$245
- Ronald GilmanRiverside$136
- James MyersRiverside$136
- Seema AminRiverside$110
- Michael BlundinRiverside$100
- E Jane CarterRiverside$75
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.